Analysis of drugs' use for the treatment of dementia in psychiatry

Cover Page

Cite item

Full Text

Abstract

BACKGROUND: The article provides an analysis of the prescriptions of a group of medications used for the prevention and treatment of dementia associated with central nervous system damage. During the period of gerontogenesis, irreversible changes occur in the human body, associated with the somatic state and mental processes in the CNS. According to the ICD-11 classification, this type of pathology is defined as neurocognitive disorders (6D80-86).

PURPOSE OF THE STUDY: Analysis of the prescription of drugs for the treatment of dementia in patients with disorders caused by neurocognitive changes due to the aging process.

MATERIALS AND METHODS: In the course of the study, the following were used: content analysis, observation method, documentary, systematic, statistical and other methods of analyzing drug prescriptions. The research base include the gerontological departments of the Sverdlovsk Regional Psychiatric Hospital. Medical documentation with the specified medications prescribed to patients aged 60 years and older with a psychiatric history.

RESULTS AND DISCUSSION: A trend has been established towards a decrease in the number of prescriptions of drugs No. 1–3, 7 (Galantamine, Memantine, Akineton and Vinpocetine, respectively) and an increase in No. 4–6 (aminophenylbutyric acid, rivastigmine, piracetam). The experts prefer drugs with nootropic effects (57% of the entire sample), which are used along with anticholinergics (14%) and anticholinesterase drugs (29%).

CONCLUSION: According to the results of the analysis, a high level of prescriptions by doctors of specialized departments have medicines numbered No. 4, 5, and 6 (aminophenylbutyric acid, rivastigmine, piracetam).

About the authors

Anna M. Kudryavtseva

Sverdlovsk Regional Clinical Psychiatric Hospital

Author for correspondence.
Email: anna.kudryavtseva210298@gmail.com
ORCID iD: 0000-0003-2937-7621
Russian Federation, Yekaterinburg

Irina N. Airo

Pyatigorsk Medical and Pharmaceutical Institute, branch of the Volgograd State Medical University

Email: irina.airo@yandex.ru
ORCID iD: 0000-0003-2650-9473

Dr. Sci. (Pharmaceuticals), Professor of the Pharmacy Department

Russian Federation, Pyatigorsk

Alexander Yu. Petrov

Ural State Medical University

Email: unitmp@yandex.ru
ORCID iD: 0000-0002-6199-9319

MD, Dr. Sci. (Pharmaceuticals), Professor

Russian Federation, Yekaterinburg

References

  1. Ostroumova OD, Starodubova AV, Ostroumova TM, Chernyaeva MS. Cognitive Disorders and Dementia in Old Patients With Arterial Hypertension. Kardiologiia. 2018;58(10):71–79. (In Russ.) EDN: YLGHJZ doi: 10.18087/cardio.2018.10.10186
  2. Parfenov VA. Dementia. Clinical gerontology. 2006;12(11):3–10. (In Russ.) EDN: JUUINT
  3. Clinical recommendations of the Russian Federation of 2020. “Cognitive disorders in the elderly and senile”. Available from: https://cr.minzdrav.gov.ru/schema/617_1 (accessed: November 8, 2023). (In Russ.)
  4. Leonova MV. Deprescribing against polypharmacy: the possibilities of the method. Pharmateka. 2019;26(9):26–34. (In Russ.) EDN: ZJYEQP doi: 10.18565/pharmateca.2019.9.26-34
  5. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589–1599. (In Russ.) doi: 10.1001/jama.2019.4782
  6. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169–182. doi: 10.1111/j.1527-3458.2005.tb00268.x
  7. Patyar S, Prakash A, Modi M, Medhi B. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618–628. doi: 10.1016/s1734-1140(11)70574-6
  8. Zakharov NB, Zlokazova MV, Semakina NV. Gender factor and mental disorders. Vyatka Medical Bulletin. 2022;75(3):77–81. (In Russ.) EDN: YQIPEI doi: 10.24412/2220-7880-2022-3-77-81

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure. Consumption of medications by departments of the Sverdlovsk Regional Clinical Psychiatric Hospital for the profile “Dementia” on average for three years (2021–2023)

Download (151KB)

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).